Pharma Mar SA
MAD:PHM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
26.24
80.75
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PHM stock under the Base Case scenario is 33.67 EUR. Compared to the current market price of 79.85 EUR, Pharma Mar SA is Overvalued by 58%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Pharma Mar SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PHM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Pharma Mar SA
Balance Sheet Decomposition
Pharma Mar SA
Current Assets | 224.1m |
Cash & Short-Term Investments | 135.1m |
Receivables | 30m |
Other Current Assets | 59m |
Non-Current Assets | 93m |
Long-Term Investments | 5.3m |
PP&E | 54.7m |
Intangibles | 1.4m |
Other Non-Current Assets | 31.5m |
Current Liabilities | 87.9m |
Accounts Payable | 32.8m |
Accrued Liabilities | 1.1m |
Short-Term Debt | 4.9m |
Other Current Liabilities | 49.2m |
Non-Current Liabilities | 47.8m |
Long-Term Debt | 27.4m |
Other Non-Current Liabilities | 20.4m |
Earnings Waterfall
Pharma Mar SA
Revenue
|
158.8m
EUR
|
Cost of Revenue
|
-10.5m
EUR
|
Gross Profit
|
148.3m
EUR
|
Operating Expenses
|
-158.2m
EUR
|
Operating Income
|
-9.8m
EUR
|
Other Expenses
|
8.1m
EUR
|
Net Income
|
-1.8m
EUR
|
Free Cash Flow Analysis
Pharma Mar SA
EUR | |
Free Cash Flow | EUR |
The company's financial highlights for the year include increased investment in Research & Development (R&D) and a rise in royalties from ZEPZELCA in the U.S. Despite facing challenges such as competition from generics affecting YONDELIS revenue in Europe, the company's balance sheet remains strong. They are advancing clinical trials and anticipate these strategies to produce positive developments. In the coming year, they expect results from several trials: Phase II of lurbi and IO, completion of LAGOON trial recruitment, and data release for Phase II of lurbi and azo. They also predict top-line PFS data from the IMforte trial and Phase III results of tivanisiran.
What is Earnings Call?
PHM Profitability Score
Profitability Due Diligence
Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
PHM Solvency Score
Solvency Due Diligence
Pharma Mar SA's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Pharma Mar SA's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHM Price Targets Summary
Pharma Mar SA
According to Wall Street analysts, the average 1-year price target for PHM is 68.14 EUR with a low forecast of 29.9 EUR and a high forecast of 107.1 EUR.
Dividends
Current shareholder yield for PHM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Contact
IPO
Employees
Officers
The intrinsic value of one PHM stock under the Base Case scenario is 33.67 EUR.
Compared to the current market price of 79.85 EUR, Pharma Mar SA is Overvalued by 58%.